Epcoritamab for Relapsed/Refractory EBV+ Post-Transplant Lymphoproliferative Disorder of DLBCL-Type

Patients with relapsed/refractory post-transplant lymphoproliferative disorder (R/R PTLD) following solid-organ transplants (SOT) or hematopoietic stem cell transplants (HSCT) after frontline chemoimmunotherapy have dismal outcomes. There is no standard of care for this group of patients, and they are generally excluded or ineligible for clinical trials. Several effective novel agents have been licensed in recent years for the treatment of diffuse large b-cell lymphoma (DLBCL), including CD19 CAR-T cell therapy and CD3xCD20 bispecific antibody.

Acknowledging the limited data and extrapolating the evidence from trials in DLBCL, we report a case of R/R PTLD successfully treated with CD3xCD20 bispecific antibody, Epcoritamab, with good tolerability and long-term response.

The authors have confirmed clinical trial registration is not needed for this submission.